意大利CART-SIE研究报告:淋巴瘤患者接受CD19靶向CAR-T细胞治疗后的第二原发恶性肿瘤
该研究分析意大利前瞻性观察性CART-SIE研究中651例接受CAR-T治疗的重度预处理淋巴瘤患者,第二原发恶性肿瘤(SPM)发生率为4.3%(28/651),以血液系统恶性肿瘤最常见,作者认为该频率相对较低且与既往研究一致。
要点
- 651例接受CAR-T治疗的患者中,SPM发生率为4.3%(28/651)。
- 最常见的SPM为血液系统恶性肿瘤。
- 作者认为该队列SPM频率相对较低,与既往研究一致。
核心结论
- 在接受CAR-T治疗的重度预处理患者队列中,SPM频率相对较低,且与既往研究一致。
研究设计与样本
- 意大利前瞻性观察性CART-SIE研究,纳入651例接受CD19靶向CAR-T细胞治疗的淋巴瘤患者。
主要发现
- SPM发生率为4.3%(28/651)。
- 最常见的SPM为血液系统恶性肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary primary malignancies (SPM) have been reported after anti-BCMA or anti-CD19 chimeric antigen receptor (CAR)-T-cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has been well established, few data are available on risk related to CAR-T immunotherapies. The study aimed to analyse the incidence of SPM in 651 patients enrolled in the Italian prospective observational CART-SIE study. SPMs were documented in 4.3% (28/651), and the most frequent SPMs were haematological malignancies. In conclusion, the frequency of SPMs in our cohort of heavily pretreated patients receiving CAR-T was relatively low and consistent with previous studies.
引用
- Barone A, Chiappella A, Casadei B, et al. Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study. Br J Haematol. 2024. PMID: 38877876. doi:10.1111/bjh.19590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。